Technology -- Cyclica

Cyclica has designed, patented, and optimized our Ligand Design technology, which can uniquely de novo design chemical entities across a panel of desirable targets while avoiding undesirable anti-targets. Driven by a metaheuristic genetic algorithm coupled with a novel AI technology that we have built internally at Cyclica called POEM (patents filed Sept 2018), Ligand Design begins by fragmenting seed molecules and derivatizing them with preferred fragment libraries to explore synthetically accessible chemical space. Ligand Design then selects amongst these hypothetical molecules for those with desirable physicochemical and pharmacokinetic properties to proceed to the next step - this is based on our internally developed ADMET-Prediction technology. Ligand Design then computes polypharmacological profiles, selects those with preferred profiles, and then initiates another cycle of Ligand Design. This process continues until a set of molecules with desirable properties are fashioned.